The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

Since July, several biotechs have been forced to pivot as previous agreements with the FDA around evidence required for approval were reversed, a phenomenon that, according to experts, could portend a ...

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target Lead asset LX2006 is an ...

Design Therapeutics (DSGN) stock gains as RBC upgrades the biotech, citing a catalyst-rich near-term outlook for the company. Read more here.

Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organizatio ...

The Oxford-Harrington Rare Disease Centre ('OHC') today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.

Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat rare and ultra-rare diseases OXFORD, England ...

Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on ...

Infectious meningoencephalitis, characterized by inflammation of both the brain and adjacent meninges, is caused by a variety ...

Researchers at the University of Innsbruck and Schoen Clinic Roseneck report that structured therapeutic climbing sessions ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...